FDA approves VYALEV for adults living with advanced parkinson's disease
VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
Buckley served as Chairman and Chief Executive Officer at Vanguard from 2018 until his retirement in 2024
India has been declared ‘functional’ against all the core regulatory functions of the WHO Global Benchmarking Tool Version VI
Strokes are affecting approximately 1.8 million people annually
Under the licensing agreement, Alkem will carry out the clinical development of “SON-080” in India with support from Sonnet and enable global and India regulatory filings
Approval is based on Phase III INAVO120 results, showing the Itovebi (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting
We now rank 3rd in pharmaceutical production by volume and 14th by value
WEF recognises company’s Bharuch manufacturing facility as a global manufacturing lighthouse
WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
Subscribe To Our Newsletter & Stay Updated